Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Almost three decades ago, the FDA allowed women back into clinical research to participate as subjects, but the representation of females remains an issue, especially in Phase I trials. A recent study ...

Galderma has reported new interim analysis data from the OLYMPIA trial of Nemluvio for the moderate-to-severe prurigo nodularis (PN).

Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

Walgreens sets sights on clinical trial network growth in recruitment drive The US pharmacy’s clinical trials business aims to address industry-wide challenges in trial recruitment and diversity.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III trials. Announced at the International AIDS Society (IAS) 2025 conference ...

Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumours The decision to expand the trial was made following the completion of monotherapy dose escalation for SON-1010.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible. At the Clinical Trials in Oncology ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the CRO to support its Phase III trial, PARA_OA_012, focused on treating OA.